SCHEMBL10636701

SCHEMBL10636701

CC(O)CNc1ccc(N)cc1S(=O)(=O)CCO

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.39
CA2 P00918 4/20 0.39
RAPGEF4 Q8WZA2 1/20 0.37
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
POLB P06746 2/20 0.36
GAA P10253 2/20 0.36
RECQL P46063 2/20 0.36
CASP6 P55212 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ELAVL1 Q15717 1/20 0.36
NSD2 O96028 1/20 0.35
APEX1 P27695 1/20 0.35
APOBEC3A P31941 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
SYK P43405 6/20 0.35
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9877965 0.87 RAPGEF4 (0.38) MAPTCA2RAPGEF4ALDH1A1KDM4E
SCHEMBL10900096 0.84 CA2 (0.40) MAPTCA2RAPGEF4ALDH1A1KDM4E
SCHEMBL8164756 0.82 CA2 (0.43) MAPTCA2RAPGEF4ALDH1A1KDM4E
SCHEMBL10359926 0.80 POLB (0.46) MAPTALDH1A1POLBTDP1L3MBTL1
SCHEMBL10595422 0.80 CA2 (0.40) MAPTCA2RAPGEF4ALDH1A1KDM4E
SCHEMBL10486552 0.80 MME (0.34) MAPTCA2RAPGEF4ALDH1A1KDM4E
SCHEMBL10622343 0.80 RAB9A (0.45) MAPTCA2ALDH1A1KDM4EPOLB
SCHEMBL9878790 0.80 CA2 (0.41) MAPTCA2RAPGEF4ALDH1A1KDM4E
SCHEMBL9879136 0.80 CYP19A1 (0.42) MAPTCA2RAPGEF4ALDH1A1KDM4E
SCHEMBL17774691 0.79 POLB (0.41) MAPTCA2RAPGEF4ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9872822-B2 Process for dyeing in the presence of oxidation bases comprising at least one sulfonic, sulfonamide, sulfone, amid or acid group and a metal catalyst, device and ready-to-use composition L'OREAL (FR) 2018-01-23 US disclosed
US-9872822-B2 Process for dyeing in the presence of oxidation bases comprising at least one sulfonic, sulfonamide, sulfone, amid or acid group and a metal catalyst, device and ready-to-use composition L'OREAL (FR) 2018-01-23 US disclosed
US-20160143826-A1 PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION L'OREAL (FR) 2016-05-26 US disclosed
US-20160143826-A1 PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION L'OREAL (FR) 2016-05-26 US disclosed
US-4785098-A BLUE DYES FOR CELLULOSE HOECHST AKTIENGESELLSCHAFT (DE) 1988-11-15 US disclosed
US-4577015-A Triphendioxazine vinyl sulphone dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1986-03-18 US disclosed
EP-0153599-A2 Triphenedioxazine vinylsulfonyl dyestuffs BAYER AG (DE) 1985-09-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160143826-A1 PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION KRT18, ARSA, SQOR MAPT 2197/4885CA2 86/4885RAPGEF4 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.